Page 67 - ARNM-1-2

Advances in Radiotherapy &

Nuclear Medicine

CASE REPORT
Evaluating the efficacy of

immunochemoradiotherapy in malignant pleural
mesothelioma and distinguishing benign from

malignant lymph nodes using F-FDG PET/CT
18
and F-FAPI-04 PET/CT imaging: A case report
18

Mengye Peng, Menglu Wang, Ying Zhang, Tingting Wu, and Kezheng Wang*
Department of PET-CT, Harbin Medical University Cancer Hospital, Harbin, China

Abstract

In this paper, we report a case of pleural mesothelioma, imaged employing
18 F-fluorodeoxyglucose (FDG) positron emission tomography/computed
tomography (PET/CT), and 18 F-fibroblast activating protein inhibitor (FAPI)-04
PET/CT. The diagnosis of pleural mesothelioma was confirmed by histopathologically
examining the thoracoscopic biopsy. The patient underwent an F-FDG PET/CT
18
before immunochemoradiotherapy, followed by an F-FAPI-04 imaging 3 months
18
after treatment. The changes in focal anatomy, morphology, and metabolic
*Corresponding author:
Kezheng Wang biology observed between the two distinct PET/CT imaging modalities can aid in
(wangkezheng9954001@163.com) distinguishing benign and malignant lymph nodes and assessing treatment efficacy.
18
Citation: Peng M, Wang M, This case highlights the diagnostic utility of F-FDG PET/C in pleural mesothelioma
18
Zhang Y, et al., 2023, and suggests that F-FAPI-04 PET/CT may serve as an effective tool for evaluating the
Evaluating the efficacy of outcomes of immunochemotherapy. Moreover, the combined application of F-FDG
18
immunochemoradiotherapy in 18
malignant pleural mesothelioma PET/CT and F-FAPI-04 PET/CT holds promise for the differentiation of benign and
and distinguishing benign from malignant lymph nodes.
malignant lymph nodes using
18 F-FDG PET/CT and F-FAPI-04
18
PET/CT imaging: A case report. Adv Keywords: F-fluorodeoxyglucose; Fibroblast activation protein inhibitor;
18
Radiother Nucl Med, 1(2): 0963
https://doi.org/10.36922/arnm.0963 Malignant mesothelioma; Positron emission tomography/computed tomography;
Immunochemoradiotherapy
Received: May 19, 2023
Accepted: September 4, 2023
Published Online: November 7,
2023 1. Background
Copyright: © 2023 Author(s). Malignant pleural mesothelioma is a rare malignant tumor. While the combination of
This is an Open-Access article cisplatin and pemetrexed represents the first-line treatment for this condition, emerging
distributed under the terms of the
Creative Commons Attribution evidence suggests the potential benefit of incorporating radiotherapy and immunotherapy
License, permitting distribution, in its management. The accurate evaluation of therapeutic efficacy carries significant
and reproduction in any medium,
provided the original work is implications for subsequent clinical decision-making and management. In this case,
18
18
properly cited. we present evidence supporting the utilization of F-fluorodeoxyglucose ( F-FDG)
Publisher’s Note: AccScience positron emission tomography/computed tomography (PET/CT) in combination with
Publishing remains neutral with 18 F-fibroblast activating protein inhibitor (FAPI)-04 PET/CT imaging as a promising
regard to jurisdictional claims in tool for evaluating the efficacy of immunochemotherapy combined with radiotherapy
published maps and institutional
affiliations in pleural mesothelioma. These imaging modalities also exhibited the capacity to

Volume 1 Issue 2 (2023) 1 https://doi.org/10.36922/arnm.0963